You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
連花清瘟概念繼續獲資金追捧 以嶺藥業連續4日漲停 年內累漲204%
格隆匯 04-16 14:48
格隆匯4月16日丨近期持續強勢的兩隻連花清瘟概念股今日繼續上漲,其中,以嶺藥業連續4日漲停,最新報37.9元,再創歷史新高價,年內累漲幅度達204%。振東製藥在連續兩日漲停後,今日繼續上漲近7%,盤中最高價元創2018年4月以來新高。

連花清瘟近日火遍國內外,4月14日,以嶺藥業發佈公告稱,公司藥品連花清瘟膠囊(顆粒)新增適應症申請獲得批准,處方藥説明書中增加“在新型冠狀病毒性肺炎的常規治療中,可用於輕型、普通型引起的發熱、咳嗽、乏力。”這意味着,連花清瘟膠囊在疫情期間的救治臨牀實踐正式被官方承認。 據悉,以嶺藥業已將其出口到加拿大、羅馬尼亞、印度尼西亞、莫桑比克、巴西、泰國等地。中國工程院院士、天津中醫藥大學校長張伯禮15日稱,泰國已經給連花清瘟頒佈許可證,可以在泰國銷售,法國也準備用連花清瘟做新冠肺炎治療的臨牀研究。不過,此前以嶺藥業發公告提醒稱連花清瘟膠囊在已獲上市許可國家/地區銷售收入佔營收比重較低。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account